ALK and lung cancer: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% to 90% of all lung cancer cases, according to data from the Surveillance, Epidemiology, and End Results (SEER) Program. The advent of targeted therapies has significantly improved the prognosis for patients with specific molecular drivers, such as ALK rearrangements [1].